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Background: Following the 2009 H1N1 Influenza pandemic, extracorporeal membrane oxygenation (ECMO)
emerged as a viable alternative in selected, severe cases of ARDS. Acute Respiratory Distress Syndrome (ARDS) is a
major public health problem. Average medical costs for ARDS survivors on an annual basis are multiple times those
dedicated to a healthy individual. Advances in medical and ventilatory management of severe lung injury and
ARDS have improved outcomes in some patients, but these advances fail to consistently “rescue” a significant
proportion of those affected.
Discussion: Here we present a synopsis of the challenges, considerations, and potential controversies regarding
veno-venous ECMO that will be of benefit to anesthesiologists, surgeons, and intensivists, especially those newly
confronted with care of the ECMO patient. We outline a number of points related to ECMO, particularly regarding
cannulation, pump/oxygenator design, anticoagulation, and intravascular fluid management of patients. We then
address these challenges/considerations/controversies in the context of their potential future implications on clinical
approaches to ECMO patients, focusing on the development and advancement of standardized ECMO clinical practices.
Summary: Since the 2009 H1N1 pandemic ECMO has gained a wider acceptance. There are challenges that still must
be overcome. Further investigations of the benefits and effects of ECMO need to be undertaken in order to facilitate the
implementation of this technology on a larger scale.
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Acute respiratory distress syndrome (ARDS) is the acute
onset of hypoxemia, accompanied by diffuse bilateral
pulmonary infiltrates and the absence of left heart failure
[1]. There are over 140,000 cases of ARDS in the United
States each year, with a mortality rate of 22-41% [2,3].
As many as 20% of patients with ARDS succumb to
refractory hypoxemia, and the quality of life among the
survivors can be significantly affected for a number of
years following the initial episode [4,5]. Moreover, the
average medical costs associated with long-term care for* Correspondence: thomas.papadimos@osumc.edu
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unless otherwise stated.ARDS survivors are approximately four times greater
than those expended for a person in good health [6].
There has been some progress in the management of
severe lung injury and ARDS in the past two decades,
including important clinical trials such as the ARDSNET
trial, investigating ventilator management techniques
associated with improved outcomes in ARDS patients
[7]. Among key findings of the most prominent clinical
investigations is the association between high ventilator
tidal volumes and worsening lung injury [7-11]. On the
other hand, the use of lower tidal volumes may improve
overall outcomes and mortality [7-11].
After the failure of conventional mechanical ventilation,
airway pressure release ventilation (APRV) and high
frequency oscillatory ventilation (HFOV) can sometimes
be used as “rescue” therapies [12]. However, the numberLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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more limited as the severity of illness progresses [13].
Extracorporeal membrane oxygenation (ECMO) is
emerging as one of these alternative, life-saving maneuvers,
mainly thanks to its successful use in the 2009 H1N1
pandemic [14-17]. ECMO is a form of partial cardiopulmo-
nary bypass (CPB) that can be employed in longer-term
support of respiratory and/or cardiac function. This tech-
nology was derived and adapted from the CPB traditionally
used during cardiac surgery. Early ECMO system designs
used “bubble oxygenators” that were poorly suited for
prolonged use because of their tendency to hemolyze
blood. Membrane oxygenators now have replaced “bubble
oxygenators” and have made the long-term use (weeks
instead of days) of ECMO possible.
Discussion
Implementation of ECMO
The first report of successful ECMO support in an adult
patient was published by Hill in 1972 [18]. ECMO can be
implemented either as veno-arterial (VA) or veno-venous
(VV) therapy. For complete cardiopulmonary support, VA
ECMO is used while primary respiratory failure including
severe oxygenation failure is usually treated with VV
ECMO. Both VA and VV approaches require a pump
that is capable of generating flow rates of 3–5 L · min−1 in
order to ensure sufficient organ perfusion and oxygenation.
This discussion will confine itself to VV ECMO used in
refractory respiratory failure, including clinical indications
of pneumonia (bacterial, fungal, viral, aspiration), status
asthmaticus, traumatic pulmonary contusions, pulmonary
embolism, as well as for secondary causes such as
ARDS associated with overwhelming sepsis or systemic
inflammatory conditions. Large bore cannulae drain
venous blood that is pumped through an oxygenator
where it is cleared of carbon dioxide, oxygenated, and then
actively returned back to the patient’s circulation. While
both ECMO and CPB use somewhat similar technologies
in terms of vascular cannulation, tubing for blood flow, and
even oxygenators and pumps, the fundamental difference is
that CPB incorporates a reservoir for adjusting real-time,
total blood volume. Because there is no such reservoir in
ECMO, meticulous attention to de-airing is critical when
establishing perfusion [19].
It is important to remember that hypoxemia, hypercarbia,
and acidosis are very potent pulmonary vasoconstrictors
and these patients often have evidence of acute right heart
failure and pulmonary arterial hypertension. Addressing
these issues with ECMO can often break the vicious and
often fatal downward spiral of hypoxemia, hypercarbic
(respiratory) acidosis, right heart failure, low cardiac
output and the resulting metabolic acidosis from im-
paired oxygen availability at the cellular level. In fact,
severe respiratory acidosis with hemodynamic instabilityrequiring vasoactive support can be an indication for
ECMO [20].
The most comprehensive guidelines on ECMO are pub-
lished by the Extracorporeal Life Support Organization
(ELSO) [21]. These guidelines address personnel, training,
resources, use of ECMO, and quality assurance. In the
subsequent sections, we will discuss the points that most
challenge a new practitioner who is newly faced with
care of the patient placed on VV ECMO and its clinical
implementation, focusing on practical clinical applicability
of this life-saving therapy.
Challenge one: who is eligible for veno-venous ECMO?
Careful selection of ECMO candidates is critical because
of potential complications and substantial costs. Indeed,
the associated high mortality may lead to a perception of
ECMO being an inefficient use of scarce resources
[3,18]. According to the ELSO guidelines the use of
ECMO should be considered when the ratio of PaO2 to
FiO2 is <150, and ECMO is indicated when the ratio is <80.
PaCO2> 80 mm Hg or end-inspiratory plateau pres-
sure >30 cm H2O is also considered an indication for
ECMO in patients with ARDS [21].
According to Brodie et al., more specific indications
for VV ECMO in the case of ARDS include severe
hypoxemia (as indicated in the ELSO guidelines) despite
the addition of high positive end expiratory pressure
(PEEP) at the 15–20 cm H2O levels for six hours in those
who have reversible respiratory failure; uncompensated
hypercapnea with a pH < 7.15 in the face of best practice
ventilator mode manipulation; and extremely high
end-inspiratory plateau pressures (40 cm H2O) [3]. Relative
contraindications include PEEP levels > 30 cm H20
for >7 days, FiO2> 80% for >7 days, limited vascular
access, and terminal cancer or severe brain injury
that cannot be reversed. Of course, those patients who
cannot receive anticoagulation must be excluded. Further
suggestions and guidelines on using ECMO to rescue
patients with severe ARDS can be found in the ongoing
EOLIA (Extracorporeal Membrane Oxygenation for
Severe Revere Respiratory Distress Syndrome) study,
conducted by Combes et al. [22], the use of the Murray
score in the CESAR Trial [19], and a study by Zapol et al.
[20]. The value of these trials is that the clinical expertise
available at an ECMO center is more than the ECMO
itself. The expertise of the anesthesiologists, intensivists,
and respiratory technologists allows for a broader depth of
practice than what is often supported by smaller referral
centers. In any event, the guidelines above may conflict
with the specific guidelines from other countries and insti-
tutions. For instance, age > 65 years is an absolute contra-
indication in some countries, while an absolute weight as
opposed to BMI may be used [23]. Who actually receives
ECMO will vary by situation, institution and geography
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for candidacy are institutional specific, there are some
controversies. For body mass index (BMI), there are
physical limits to who can be cannulated and supported. If
one has a BMI greater than 35 kg/m2, the perfusion circuit
may not be able to generate enough flow without high line
pressures. The elevated line pressure will lead to hemolysis
over time. Unfortunately, obesity is an epidemic and the
proportion of the population in developed countries above
a BMI of 30 is increasing. An absolute BMI may be a
relative contraindication or soft limit, from center to center.
If a patient has been on maximal support for >7 days,
the extent to when they may be recoverable in a time
period before adverse events occur comes into question.
Prolonged ECMO runs lead to hemolysis, elevated LDH,
elevated bilirubin and liver function tests, and even
carbon monoxide (CO) poisoning (In ECMO, hemolysis is
frequently a problem, especially secondary to disruption
of the hemoglobin molecule by mechanical trauma from
the ECMO cannulas. When hemoglobin is degraded, free
iron, biliverdin and CO are produced by heme oxygenase
enzymes). This can in turn lead to a coagulopathy and
need for replacement of oxygenators/circuits. In addition,
prolonged illness can lead to multi-system organ failure.
Additionally, withholding ECMO support may be con-
sidered in a patient with repeated suicide attempts
without previous psychological treatment and/or sup-
port. There are several indices that have been studied (e.g.,
SOFA, APACHE) which can prognosticate on the degree
of illness and their association with survival. They
may have value in ECMO decision management. Once
a practitioner or team have decided to place a patient on
ECMO, a palliative care team should be consulted to
help the patient and/or their family determine the
goals of care.Figure 1 Examples of VV femoral cannulization. (A) femoral-femoral coChallenge two: choosing the cannula type
VV ECMO requires only venous access. Usually the
access is accomplished using any combinations of femoral
vein(s) (Figure 1), internal jugular vein(s) or subclavian
vein(s). Ultrasound guidance in conjunction with the
Seldinger technique may be helpful. VV ECMO can
be administered with one cannula or two [25,26].
Typically, in situations involving ARDS, two catheters
are placed via the femoral approach; however, this
practice may vary from center to center. A drainage or
outflow catheter is placed above the confluence of the iliac
veins and the inferior vena cava and must be confirmed
radiographically. The umbilicus may be used as an
anatomical landmark externally. The inflow cannula is
placed into the right atrium with the nipple as the
external landmark. This allows blood drained from
the abdomen and lower extremities to be oxygenated and
returned to the right heart circulation. The final result is
an optimization of systemic perfusion (normal cardiac
function is required for this supposition).
The development of a bicaval dual lumen (BCDL)
catheter (Avalon Laboratories, Rancho Dominguez, CA)
has allowed for both inflow and outflow ports at a
single site. However, the use of this technology can be
challenging due to the complexity of catheter placement.
Precise placement of the BCDL catheter is required to
ensure correct direction of the reinfusion jet towards
the tricuspid valve. BCDL catheter placement is often done
with fluoroscopy and/or transesophageal echocardiography
(TEE) [27,28].
There are both advantages and disadvantages to the
BCDL catheter [28]. Advantages include (a) single
insertion site, which decreases risk of bleeding and
infection, (b) ability to ambulate patients (Figure 2), (c)
posterior lateral position that is optimal for thoracicnnection; (B) femoral jugular connection.
Figure 2 Example of ECMO ambulation: (A) extubated, bed-ridden patient on ECMO; (B) patient on ECMO and able to sit up in bed
and ambulate.
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and (e) facilitates aeromedical transport. In contrast,
the disadvantages include (a) limited range of catheter
sizes with limited flows if inappropriate size inserted,
(b) radiographic and/or echocardiographic guidance
needed for insertion, (c) instability of catheter after
placement, (d) insertion of a large, double lumen cannula
into the internal jugular artery may result in cerebral
venous congestion; an additional cephalad drainage line
may be worth considering, and (e) the need for expertise
in ECMO management for optimal outcomes. We use the
BCDL frequently because we try to keep our ECMO
patients ambulating and using a stationary bicycle type
device whenever possible, recovery permitting.
Challenge three: oxygenators and pump design
The main components of the ECMO circuit are the
oxygenator and the pump. Draining from the outflow
cannula, blood enters the pump and is driven through
the oxygenator. The oxygenated blood is returned to the
patient via the inflow cannula [29]. The circuit has three
primary modifiable settings that are (a) the pump speed,
which determines the flow of blood through the circuit;
(b) the gas “sweep” that determines the level of gas
exchange with the blood and hence assists in carbondioxide removal; and (c) oxygen setting, much like
the ventilator, is the amount of oxygen supplementation
to the blood passing through the circuit. Control and
monitoring of the system are done with a computer, which
governs flows and driveline pressures with gas regulators
to adjust oxygen support and carbon dioxide removal.
External cooling and heating systems can be incorporated
for clinical purposes, such as induced hypothermia.
Previous oxygenators were made of silicon membranes,
whereas newer oxygenators have multiple hollow fibers of
diameters less than 0.5 mm that are coated with poly-
methylpentene which allow for diffusion of gas, but not
liquid. The newer oxygenators are more efficient (with less
volume needed), more effective in gas exchange, cause less
platelet and plasma protein loss, and even have thrombo-
resistant coatings. However it is still important that pre and
post membrane pressures are monitored in order to iden-
tify thrombus formation and the potential for membrane
failure. With the use of polymethylpentene hollow fiber
membranes, once the difference pressure across the mem-
brane begins to increase it may progress more rapidly than
previously seen in the older silicone plastic membranes,
resulting in the need for emergent membrane replacement.
The most popular pump technology in use is the
centrifugal pump. Traditionally, pumps had propellers
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from friction contributed to complications such as
hemolysis, and in rare cases, melting the plastic of the
pump itself. This problem has been resolved in newer
pumps by the use of an impeller and suspending
components of the pump magnetically, which minimizes
direct contact and friction [30], thereby also allowing the
use of small bearings. Be aware that centrifugal devices are
pre-load and after- load sensitive pumps, i.e., the flow rate
varies with the drainage volume and the pressure head
being encountered. The traditional roller pumps have a
constant flow and can fail or perform poorly secondary to
high line pressure and inadequate drainage.
Challenge four: transporting ECMO patients
Improved engineering designs have significantly reduced
the footprint of ECMO units and circuits, making travel
much easier and more convenient [31]. Transport of
ARDS patients, especially in military conflict can be
challenging, let alone moving a small child or infant
any distance. In centers with limited ECMO expertise,
inter-hospital transfer may be a necessity. Optimally,
patients who may require ECMO should be identified
early and transported to a referral center (or center
of excellence) that provides ECMO expertise. The
practitioner must always be aware that the new transport
technologies present a significant cost that may or may
not necessarily be of benefit to the patient [32]. For
example, in the Maquet Cardiohelp (22 pounds) portable
device (Figure 3), the oxygenator and pump are one unit
and can “clot” together, which may be problematic. Other
modular ECMO may be used, such as the Lifebridge
devices (the B2T model weighs 36 pounds), but alwaysFigure 3 Maquet Cardiohelp portable device.recognize the logistics of transport are exceedingly
cumbersome [33]. Other devices include the configuration
of the older Medtronic system, the Maquet Rotoflow, and
the Thoratec CentriMag system.
The United States Air Force has assembled Critical Care
Air Transport Teams (CCATT) that ferry critically ill and
injured patients with lung injuries from combat/disaster
areas. Combat related thoracic injures and ARDS led to a
refinement of the CCATT concept which evolved into
The Landstuhl Acute Lung Resue Team (ALerT) that uses
pumpless extracorporeal lung assistance when necessary
to transport patients [34,35]. This type of transport has
also been duplicated successfully between children’s
hospitals recently in Columbus, Ohio [36]. It is evident
that protocol driven rescues are taking place, and while
the protocols may vary from organization to organization,
the miniaturization of devices has changed the face of
transport dramatically.
Challenge five: transfusion and intravascular fluid
management
The absence of the reservoir for real-time adjustments
of blood volume in VV ECMO permits lower levels of
anticoagulation that minimize clotting of the circuit.
However, the lack of this reservoir creates a potential
disadvantage in that more active management is required
in order to optimize the patient’s intravascular volume
status. Consequently, ECMO patients require infusion of
additional fluids via central or peripheral intravenous
access, or via the ECMO circuit itself when additional
volume is needed. Volume management in VV ECMO is
assisted by the fact that the circuit has a heating ability
(and also a cooling ability to allow for neuroprotection
Tulman et al. BMC Anesthesiology 2014, 14:65 Page 6 of 11
http://www.biomedcentral.com/1471-2253/14/65in the event of a cardiopulmonary arrest or a severe
febrile state).
In VV ECMO, mechanical ventilation is minimized
and hematocrit is kept at around 40%; SpO2 of 80% and
PaO2 of 40 mm Hg are acceptable (the basis for this
statement can be reviewed in the ELSO guidelines and
by a review of the equations involved with the oxygen
content of arterial and venous blood). However, the
benefit gained from maintaining high hematocrit has to
be carefully considered in the context of known harmful
effects of transfusion [37,38]. Blood is associated with
increased mortality [39], transmission of viruses [40], and
greater risk of infections in general [41]. Brodie et al.
recommend using the same transfusion thresholds as
those used in the care of patients with ARDS who are not
being treated with ECMO [3].
There are several indicators of volume depletion in a
VV ECMO patient. When intravascular volume is
depleted or compromised the ECMO cannulas swing
back and forth (chattering of lines). The traditional
response has been to give fluid, or in the case of a
hematocrit of less than 40%, to transfuse packed red
blood cells. Additionally, in regard to volume status,
monitoring of the relative changes in a central venous
pressure line may be of help. Additionally, for centrifugal
pumps, the fluctuating of the flow rate markedly over a
rather short period of time (second to minutes) may be
foretelling. Also, simply the documentation of a decrease
flow may assist in decision-making. This appears to
occur because the cava/atrium is being sucked down on
the cannula and the speed needs to be cycled (decreased
then ramped up again) to correct this situation (as you
would do if your vacuum cleaner sucked up a rug); such
patterns indicate hypovolemia or excessive pump speed
or cannula malposition. Be aware that an increase of 10%
body weight secondary to fluid accumulation leads to
increased mortality [42]. This approach leads to an
accumulation of fluid that may be removed with diuresis/
pharmacologically or by the use of renal replacement
therapy. Our experience is to maintain a slightly negative
fluid balance as tolerated by the patient.
Transiently decreasing the output of the pump is
preferable over administration of intravenous fluid if
extracorporeal blood flow is compromised by depletion of
intravascular volume [3]. This approach may require
intermittent increases of the ventilator support (i.e., FiO2)
to maintain adequate oxygenation in the face of temporarily
lower blood flows within the ECMO circuit. This maneuver
can be reversed once the intravascular volume is restored
and/or optimized.
Challenge six: anticoagulation
Anticoagulation is necessary during active ECMO
therapy because of the high thrombogenicity associatedwith blood coming into direct contact with the extracor-
poreal tubing. Bleeding and thromboembolic events may
be the most frequent causes of death [43]. Most ECMO
tubing circuits are heparin-bonded which can minimize
the coagulation risk or provide some antithrombotic
protection without systemic anticoagulation for short
periods of time. Heparin bonding typically wanes after
1–2 days, which might be enough time to control
surgical bleeding or reduce the risk of initial bleeding
complications in high-risk patients. Typically heparin is
used with conventional nomograms of dosing. Usually an
aPTT is targeted to the range of 60–80 seconds, but
this varies from institution to institution. One major
drawback is that heparin leads to heparin-induced
thrombocytopenia (HIT) syndrome in 10-15% of ECMO
patients [44,45].
Another anticoagulation option is bivalirudin, which
was first used successfully in ECMO in a patient with
acute HIT [46]. Bivalirudin may result in less clotting of
the circuit and fewer bleeding complications. In 21 ECMO
patients receiving bivalirudin, Ranucci et al. demonstrated
the efficacy of bivalirudin compared to heparin with
regard to coagulation profile, less bleeding associated
with bivalirudin, and the safety of bivalirudin as the
sole coagulant for postcardiotomy ECMO [47]. Patients
who received bivalirudin received fewer allogenic
transfusions and experienced reduced costs compared
to heparin. Due to the small numbers and retrospective
nature of the study, its impact is limited and further
investigation of bivalirudin use in ECMO patients is
warranted. Practitioners must be aware that direct
thrombin inhibitors have a high cost and do not have
an antidote (reversal agent) [47].
One future option may be to avoid the use of anticoagu-
lant. A newly developed circuit allowed 151 days of ECMO
in an animal model with a trivial amount of heparin [48].
The development of the T-NCVC coating system, a
complex of bonded heparin and aliphatic coupling reagents,
may prevent heparin from leaching into the ECMO system.
When the material comes in contact with blood, heparin is
retained on the surface of the material. The activated clot-
ting time (ACT) and aPTT were kept in the physiologic
range and plasma heparin was not detected until the 21st
week. Platelet levels decreased for the first 4 weeks, but then
remained constant. No elevation of plasma free hemoglobin
occurred and hemoglobin levels were maintained through
the 20th week. The pump and oxygenator were essentially
free of thrombus. The study had to be terminated because
hemolysis occurred after 151 days on ECMO and there
were problems with the centrifugal pump.
Challenge seven: the airway
The practitioner should remember that there is little
doubt that the patient with severe ARDS requiring ECMO
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option for patient comfort and ease of care of the airway.
However, the necessity of keeping VV ECMO patients
intubated is being investigated, especially since the
modern bicaval dual lumen catheter facilitates ambulation.
In centers with the appropriate experience, patients wait-
ing for lung transplantation are extubated and encouraged
to ambulate and participate in active rehabilitation [49,50].
Participation in physical therapy in this manner prevents
deconditioning and improves long-term outcome [51].
Ultimately, patients may not require endotracheal intub-
ation to survive, although an established airway facilitates
bronchoscopy and airway clearance. In fact, it has been
recently demonstrated retrospectively that patients do not
have to be intubated during bridging to lung transplant-
ation and can be managed successfully in this manner
[52,53]. Lastly, it is important to remember that the
duration of pre-ECMO intubation has been associated
with lower likelihood of decannulation [54].
Challenge eight: neuromuscular blocking agents
Neuromuscular blocking agents (NMBAs) have been
controversial in regards to their efficacy in treating
ARDS. Due to lack of evidence on a large scale, no clear
recommendations exist regarding the use of NMBAs in
ARDS. However, some studies suggest that anesthesia
and paralysis cause a ventilation/perfusion mismatch
and impair gas exchange [55].
Recent developments assert that the hypoxemia in
ARDS reaches its worst levels in the first 48 hours. The
traditional view on NMBA use in the critical care setting is
largely negative, with a number of potential complications
associated with this therapeutic modality [56-58]. In a
study of 56 patients with ARDS, improved oxygenation
was seen in patients randomized to NMBAs in the first
48 hours while receiving volume assist control with a tidal
volume of 6–8 ml/kg [59]. Another similar study reported
that early NMBA use may contribute to modulation of
the pro- inflammatory response [60]. Additionally, a
third study of 340 patients where cis-atracurium was
administered in the first 48 hours of development of
ARDS found that the NMBAs improved the adjusted
90-day survival and increased time off of the ventilator
without increasing muscle weakness [61]. Neto et al.
performed a systematic review of the literature and
meta-analysis of studies conducted between 1966 and
2012, and the three above-mentioned studies were the
only acceptable, high-quality trials performed [62].
The authors concluded, based on these three studies, that
that the use of NMBAs in the early stages of ARDS leads
to an improved outcome. Nonetheless, further trials may
need to be performed to solidify such a conclusion. The
general sedation of the VV ECMO patient is beyond the
scope of this synopsis, but sedation of the patient requiresforethought and constant reevaluation. Never forget to
sedate a patient in which a NMBA is used. As indicated,
the above suppositions related to NMBAs were not
directly related to ECMO, but difficulty in oxygenating an
ECMO patient should at least lead to the consideration of
pharmacologic paralysis.
Challenge nine: the hospitals
Analyzing the differences across medical centers is a
challenge in itself, especially since level of expertise can
widely vary even within a single hospital. The CESAR
Trial and corresponding analysis compared conventional
practice and ECMO treatment in only one institution
[63,64]. Ninety ARDS patients were randomized to
receive “best practice” conventional treatment, and 90
were randomized to receive VV-ECMO. Three-quarters of
the patients who were randomized to ECMO at a referral
care center. Of the 90 transfers to the ECMO center, 17
did not need ECMO because the staff at the referral center
was more effective in ventilator management. Of those
that were stabilized through expert use of mechanical
ventilation, 14 out of 17 survived. More patients were
alive at 6 months than the control group (not of statistical
significance), but more survived without disability. Referral
for ECMO was also associated with .03 quality-adjusted
years at 6 months.
This trial suggested that patients on ECMO do better
at hospitals that are more experienced with ECMO. This
conclusion is further supported by subsequent studies.
Freeman et al. studied the impact of ECMO patient
volume on mortality in the pediatric and neonatal
population [65]. They retrospectively examined 7322
pediatric patients less than 18 years of age and demon-
strated that low annual volume is associated with a higher
mortality. Furthermore, they suggest that a minimum
threshold volume be established to define a regional facility
as a center of excellence (a volume of 22 ECMO patients
was needed for excellence in care). Similar findings of the
importance of ECMO patient volume were also reported
by Karamlou et al. Karamlou and colleagues reviewed
3867 cases of ECMO that were identified in a pediatric
congenital heart surgery program. They also suggested
development of regional centers of excellence [66].
Michaels et al. demonstrated the same advantage in
regard to adults [67]. Finally, Davis et al. concurred that
the use of specialized centers with adequate patient
volume led to good ECMO results in children in need of
diaphragmatic hernia repair [68].
Improved pump design and membrane technology,
along with simplified circuit design have prompted many
hospitals that do not offer ECMO to place patients on
bypass with the intention of transporting them to
ECMO referral center (centers of regional excellence).
The decision to provide ECMO, in effect, is taken out
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in patients who may have otherwise been excluded
receiving ECMO support. On the other hand, patients
may be placed on ECMO, who may have otherwise been
managed by more conventional means by experts at
centers of excellence. Positive outcomes are facilitated if
the center of ECMO expertise assists in the training of
peripheral hospitals in providing the initial training and
support of such staff.
Summary
Choosing who receives ECMO treatment is outlined in
ELSO protocols, but there are many considerations that
must be weighed as indicated in this synopsis. Essential
considerations are the futility of treatment and the safety
of anticoagulation. There are a variety of other issues
that are not as widely agreed upon, and are left to the
discretion and experience of the treatment team. Each
patient must be evaluated in the context of specific
co- morbidities and conditions present, ranging from
uncorrected surgical/anatomical problems, morbid obesity,
and any other relevant concerns. Another critical, over-
arching message that needs to be considered before placing
a patient on ECMO support is the fact that one of the most
significant mortality risks associated with this therapy
is the extra pulmonary organ function at the time of
initiation of ECMO therapy [69].
Using a single cannula with a branched inflow-outflow
design BCDL catheter has many advantages over the
more traditional two-cannula approach [70]. Currently,
the technology and development state of the single-site
ECMO support is the primary restriction that is limiting
wider use. First and foremost, there are a limited number
of ECMO-capable facilities that can manage ECMO via a
bicaval dual lumen catheter [71,72]. Additionally, there
are restrictions regarding the catheter itself, specifically
the limited size availability that can lead to complications/
limitations in flow. The complexity of placement with the
need for radiographic and/or TEE guidance remains
to be a hindrance, and the answer to this particular
challenge may be wider adoption and implementation
of high-fidelity ECMO simulation [73-75].
Pump design in ECMO technology has vastly improved
[76], which has resulted in resolution of technical compli-
cations, such as hemolysis as a result of heat from the
pump components [77,78].
However, centrifugal pumps are not flawless despite their
advances. They are still preload and afterload sensitive.
If there is a downstream occlusion of the pump circuit
(afterload increase), the centrifugal pump will continue to
spin but will not move blood volume forward. Likewise, if
there is a reduction in available drainage/inflow volume
or any occlusion of the inflow cannula, the pump will suck
down on the tubing and generate significant negativepressures that will result in hemolysis and, more
importantly, cause an acute drop in blood flow. However,
these events can often be managed by reducing the pump
flow/speed to decrease or eliminate the suction process
and allow time to troubleshoot the cause [78].
Anticoagulant is an indispensable part of the ECMO
process, requiring frequent monitoring and review [79].
The current standard is heparin, but bivalirudin is a
promising alternative that can be easily implemented.
Despite the fact that conclusive evidence on bivalirudin is
still quite limited, the few studies conducted, albeit retro-
spectively with small sample sizes, suggest that bivalirudin
is a superior alternative to heparin [46]. Caution still needs
to be exercised when using bivalirudin, especially since a
number of potential complications of this therapy have
been reported [80,81]. The use of argatroban has also been
described in the setting of HIT, as outlined by Mejak et al.
[82]. Experimentally, an ECMO circuit using trivial amounts
of anticoagulant has proven interesting. There may be
limited need for anticoagulant by using a new type of
coating, [83,84]. The equipment is still in testing phases
but may hold great promise in the future [85].
Differences in ECMO expertise and preferences across
hospitals continue to vary. Consequently, patient outcomes
may not be fully reflective of the technology itself. In
centers of excellence where the staff are considered experts
in both mechanical ventilation and ECMO, patients have a
likelihood of a positive outcome. In cases where chances
of mortality are extremely high, ECMO is certainly an
appealing option [63]. Unfortunately ECMO’s usage in
“last-resort” type situations can often overvalue its lifesav-
ing potential if the pretreatment mortality prediction is
overestimated [69,86].
There is evidence that further investigations addressing
paralysis with NMBAs in patients with ARDS treated with
ECMO should be pursued [61,87,88]. Unfortunately, the
effectiveness in the improvement of oxygenation or lung
function was not clearly addressed in these reports, so a
consensus on NMBAs remains controversial. The majority
of the current research focuses on long term effects rather
than the benefit of NMBAs during the first few days of
ARDS. It is suggested that the worst hypoxemia occurs
during this early period and thus a major reason why
NMBA’s may play a pivotal role in recovery.
ECMO was successfully used in the 2009 H1N1
pandemic and subsequently gained a wider audience,
demonstrating great potential in ameliorating patient
outcomes. There are still a myriad of unique challenges
that must be overcome and understood in the ongoing
development process for advancing and standardizing
ECMO practices. Many of the issues plaguing the early
advance of ECMO have seen technological progression
and resolution making it a much more viable, and efficient
option. Further study needs to be undertaken in order to
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well as improve the implementation of the technology
on a wider scale.
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